Skip to Content
Merck
  • Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial.

Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial.

PloS one (2014-10-10)
Claudia Gagnon, Robin M Daly, André Carpentier, Zhong X Lu, Catherine Shore-Lorenti, Ken Sikaris, Sonia Jean, Peter R Ebeling
ABSTRACT

To examine whether combined vitamin D and calcium supplementation improves insulin sensitivity, insulin secretion, β-cell function, inflammation and metabolic markers. 6-month randomized, placebo-controlled trial. Ninety-five adults with serum 25-hydroxyvitamin D [25(OH)D] ≤55 nmol/L at risk of type 2 diabetes (with prediabetes or an AUSDRISK score ≥15) were randomized. Analyses included participants who completed the baseline and final visits (treatment n = 35; placebo n = 45). Daily calcium carbonate (1,200 mg) and cholecalciferol [2,000-6,000 IU to target 25(OH)D >75 nmol/L] or matching placebos for 6 months. Insulin sensitivity (HOMA2%S, Matsuda index), insulin secretion (insulinogenic index, area under the curve (AUC) for C-peptide) and β-cell function (Matsuda index x AUC for C-peptide) derived from a 75 g 2-h OGTT; anthropometry; blood pressure; lipid profile; hs-CRP; TNF-α; IL-6; adiponectin; total and undercarboxylated osteocalcin. Participants were middle-aged adults (mean age 54 years; 69% Europid) at risk of type 2 diabetes (48% with prediabetes). Compliance was >80% for calcium and vitamin D. Mean serum 25(OH)D concentration increased from 48 to 95 nmol/L in the treatment group (91% achieved >75 nmol/L), but remained unchanged in controls. There were no significant changes in insulin sensitivity, insulin secretion and β-cell function, or in inflammatory and metabolic markers between or within the groups, before or after adjustment for potential confounders including waist circumference and season of recruitment. In a post hoc analysis restricted to participants with prediabetes, a significant beneficial effect of vitamin D and calcium supplementation on insulin sensitivity (HOMA%S and Matsuda) was observed. Daily vitamin D and calcium supplementation for 6 months may not change OGTT-derived measures of insulin sensitivity, insulin secretion and β-cell function in multi-ethnic adults with low vitamin D status at risk of type 2 diabetes. However, in participants with prediabetes, supplementation with vitamin D and calcium may improve insulin sensitivity. Australian New Zealand Clinical Trials Registry ACTRN12609000043235.

MATERIALS
Product Number
Brand
Product Description

USP
Calcium Carbonate (AS), United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Calcium carbonate, CP
Sigma-Aldrich
Calcium carbonate, ACS reagent, chelometric standard, 99.95-100.05% dry basis
Sigma-Aldrich
Calcium carbonate, BioUltra, precipitated, ≥99.0% (KT)
Sigma-Aldrich
Calcium carbonate, tested according to Ph. Eur.
Sigma-Aldrich
Calcium carbonate, ≥99.995% trace metals basis
Sigma-Aldrich
Calcium carbonate, 99.999% trace metals basis
Sigma-Aldrich
Calcium carbonate, powder, ≤50 μm particle size, 98%
Sigma-Aldrich
Calcium carbonate, BioReagent, suitable for insect cell culture, ≥99.0%
Sigma-Aldrich
Calcium carbonate, BioXtra, ≥99.0%
Supelco
Calcium carbonate, reference material for titrimetry, certified by BAM, ≥99.5%
Sigma-Aldrich
Calcium carbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E170, precipitated, 98.5-100.5% (based on anhydrous substance)
Supelco
Calcium carbonate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Calcium carbonate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Calcium carbonate, ReagentPlus®
Sigma-Aldrich
Calcium carbonate, ACS reagent, ≥99.0%, powder